Orchard Therapeutics plc (NASDAQ:ORTX) finished Friday with a subtraction of $0.0 to close at $0.37, an upside of 1.34 percent. An average of 508,340 shares of common stock have been traded in the last five days. There was a fall of -$0.0090 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 617,920 shares traded, while the 50-day average volume stands at 355,044.
ORTX stock has decreased by -16.12% in the last month. The company shares reached their 1-month lowest point of $0.3601 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.36 and a high of $1.55 in 52 weeks. It has reached a new high 1 time so far this year and lost -71.89% or -$0.9490 in price. In spite of this, the price is down -76.06% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Orchard Therapeutics plc (ORTX) stock’s beta is 0.68. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.91, the price-to-book (PB) ratio at 0.38.
The quick ratio of Orchard Therapeutics plc for the three months ended June 29 was 3.50, and the current ratio was 3.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.20 and a total debt to equity ratio of 0.27 for the quarter ending June 29. Its gross profit as reported stood at $1.45 million compared to revenue of $1.68 million.
For the three-month period that ended June 29, Orchard Therapeutics plc had $65.8 million in cash and short-term investments compared to $25.27 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$47.57 million in the quarter, while revenues were grew 23.38%. The analyst consensus anticipated Orchard Therapeutics plc’s latest quarter earnings to come in at -$0.26 per share, but it turned out to be -$0.4, a -53.80% surprise. For the quarter, EBITDA amounted to -$24.94 million. Shareholders own equity worth $126.69 million.
From a technical analysis perspective, let’s take a brief look at Orchard Therapeutics plc (ORTX) price momentum. RSI 9-day as of the close on 30 December was 29.92%, suggesting the stock is oversold, with historical volatility in this time frame at 26.23%.
As of today, ORTX’s price is $0.3698 -2.37% or -$0.0090 from its 5-day moving average. ORTX is currently trading -15.68% lower than its 20-day SMA and -37.12% lower than its 100-day SMA. However, the stock’s current price level is -17.17% below the SMA50 and -48.72% below the SMA200.
The stochastic %K and %D were 4.54% and 3.35%, respectively, and the average true range (ATR) was 0.0233. With the 14-day stochastic at 6.82% and the average true range at 0.0237, the RSI (14) stands at 32.84%. The stock has reached -0.0107 on the 9-day MACD Oscillator while the 14-day reading was at -0.0347.
The consensus rating for Orchard Therapeutics plc (ORTX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ORTX, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 4 others rate it as a “buy”.
What is ORTX’s price target for the next 12 months?
Analysts predict a range of price targets between $1.00 and $5.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for Orchard Therapeutics plc (ORTX) stock is $3.33.